Movicolon

Macrogol 3350, the active ingredient in Movicolon, is an osmotic laxative presented as a powder for oral use. Combined with sodium hydrogen carbonate, potassium chloride and sodium chloride, the formulation draws water into the intestinal lumen, softening stool and facilitating bowel movements. It is indicated for the relief of occasional constipation and for bowel cleansing prior to colonoscopy or other diagnostic procedures in adult patients.

GNH USA supplies Movicolon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity across markets.

Movicolon is used as an osmotic laxative to manage conditions related to bowel clearance and constipation. - Constipation: provides gentle, water‑based stool softening to facilitate regular bowel movements. - Bowel preparation for colonoscopy: cleanses the colon by increasing intestinal water content, enabling clear visualization during endoscopic procedures. - Chronic idiopathic constipation: supports long‑term management by regularly softening stool and reducing the need for stimulant laxatives. - Pre‑operative bowel cleansing: prepares the gastrointestinal tract before surgical interventions requiring an empty colon.

Movicolon may cause a range of adverse reactions, most of which are mild and related to its osmotic activity.

Common Side Effects: - Abdominal bloating: sensation of fullness in the abdomen. - Flatulence: increased intestinal gas. - Nausea: mild feeling of queasiness. - Diarrhea: loose or watery stools. - Abdominal cramps: intermittent stomach pain. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Severe dehydration: marked loss of body fluids. - Electrolyte imbalance: abnormal potassium or sodium levels. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Persistent abdominal pain: intense, ongoing discomfort. - Rectal bleeding: blood in stool or on toilet paper. - Acute renal impairment: sudden decline in kidney function.

Before prescribing Movicolon, healthcare professionals should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust use if necessary. - Electrolyte disorders: avoid in patients with existing hyper‑ or hyponatremia or hyperkalemia. - Bowel obstruction: contraindicated in complete mechanical obstruction of the intestine. - Inflammatory bowel disease: use with caution in active Crohn’s disease or ulcerative colitis. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Movicolon can interact with other medicines that affect fluid or electrolyte balance, as well as with agents that share similar laxative mechanisms.

Major Interactions (Avoid): - Potassium‑sparing diuretics: may increase risk of hyperkalemia. - ACE inhibitors or ARBs: combined effect on sodium balance can lead to hypotension. - Other osmotic laxatives (e.g., lactulose): may cause excessive fluid loss and electrolyte disturbances.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor electrolytes for additive sodium loss. - NSAIDs: may increase risk of renal impairment when combined with dehydration. - Antacids containing sodium bicarbonate: may alter electrolyte composition.